PMC:7402624 / 26492-28081 JSON TXT

Annnotations TAB JSON ListView MergeView

LitCovid-PD-FMA-UBERON

LitCovid-PubTator

LitCovid-PD-MONDO

LitCovid-PD-CLO

LitCovid-PD-CHEBI

LitCovid-PD-GO-BP

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T64","span":{"begin":223,"end":229},"obj":"http://purl.obolibrary.org/obo/GO_0007613"},{"id":"T65","span":{"begin":1576,"end":1588},"obj":"http://purl.obolibrary.org/obo/GO_0006954"}],"text":"B cell subpopulations were also altered in COVID-19 disease. Whereas naïve B cell frequencies were similar in COVID-19 patients and RD or HD, the frequencies of class-switched (IgD−CD27+) and not-class-switched (IgD+CD27+) memory B cells were significantly reduced (Fig. 4A). Conversely, frequencies of CD27−IgD− B cells and CD27+CD38+ PB were often robustly increased (Fig. 4, A and B). In some cases, PB represented \u003e30% of circulating B cells, similar to levels observed in acute Ebola or Dengue virus infections (42, 43). However, these PB responses were only observed in ~2/3 of patients, with the remaining patients displaying PB frequencies similar to HD and RD (Fig. 4B). KI67 expression was markedly elevated in all B cell subpopulations in COVID-19 patients compared to either control group (Fig. 4C). This observation suggests a role for an antigen-driven response to infection and/or lymphopenia-driven proliferation. Higher KI67 in PB may reflect recent generation in the COVID-19 patients compared to HD or RD. CXCR5 expression was also reduced on all major B cell subsets in COVID-19 patients (Fig. 4D). Loss of CXCR5 was not specific to B cells, however, as expression was also decreased on non-naïve CD4 T cells (Fig. 4E). Changes in the B cell subsets were not associated with co-infection, immune suppression, or treatment with steroids or other clinical features, though a possible negative association of IL-6 and PB was revealed (fig. S5A). These observations suggest that the B cell response phenotype of COVID-19 disease was not simply due to systemic inflammation."}

LitCovid-PD-HP

{"project":"LitCovid-PD-HP","denotations":[{"id":"T9","span":{"begin":896,"end":907},"obj":"Phenotype"}],"attributes":[{"id":"A9","pred":"hp_id","subj":"T9","obj":"http://purl.obolibrary.org/obo/HP_0001888"}],"text":"B cell subpopulations were also altered in COVID-19 disease. Whereas naïve B cell frequencies were similar in COVID-19 patients and RD or HD, the frequencies of class-switched (IgD−CD27+) and not-class-switched (IgD+CD27+) memory B cells were significantly reduced (Fig. 4A). Conversely, frequencies of CD27−IgD− B cells and CD27+CD38+ PB were often robustly increased (Fig. 4, A and B). In some cases, PB represented \u003e30% of circulating B cells, similar to levels observed in acute Ebola or Dengue virus infections (42, 43). However, these PB responses were only observed in ~2/3 of patients, with the remaining patients displaying PB frequencies similar to HD and RD (Fig. 4B). KI67 expression was markedly elevated in all B cell subpopulations in COVID-19 patients compared to either control group (Fig. 4C). This observation suggests a role for an antigen-driven response to infection and/or lymphopenia-driven proliferation. Higher KI67 in PB may reflect recent generation in the COVID-19 patients compared to HD or RD. CXCR5 expression was also reduced on all major B cell subsets in COVID-19 patients (Fig. 4D). Loss of CXCR5 was not specific to B cells, however, as expression was also decreased on non-naïve CD4 T cells (Fig. 4E). Changes in the B cell subsets were not associated with co-infection, immune suppression, or treatment with steroids or other clinical features, though a possible negative association of IL-6 and PB was revealed (fig. S5A). These observations suggest that the B cell response phenotype of COVID-19 disease was not simply due to systemic inflammation."}

LitCovid-sentences

{"project":"LitCovid-sentences","denotations":[{"id":"T159","span":{"begin":0,"end":60},"obj":"Sentence"},{"id":"T160","span":{"begin":61,"end":275},"obj":"Sentence"},{"id":"T161","span":{"begin":276,"end":387},"obj":"Sentence"},{"id":"T162","span":{"begin":388,"end":525},"obj":"Sentence"},{"id":"T163","span":{"begin":526,"end":679},"obj":"Sentence"},{"id":"T164","span":{"begin":680,"end":811},"obj":"Sentence"},{"id":"T165","span":{"begin":812,"end":929},"obj":"Sentence"},{"id":"T166","span":{"begin":930,"end":1024},"obj":"Sentence"},{"id":"T167","span":{"begin":1025,"end":1118},"obj":"Sentence"},{"id":"T168","span":{"begin":1119,"end":1239},"obj":"Sentence"},{"id":"T169","span":{"begin":1240,"end":1462},"obj":"Sentence"},{"id":"T170","span":{"begin":1463,"end":1589},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"B cell subpopulations were also altered in COVID-19 disease. Whereas naïve B cell frequencies were similar in COVID-19 patients and RD or HD, the frequencies of class-switched (IgD−CD27+) and not-class-switched (IgD+CD27+) memory B cells were significantly reduced (Fig. 4A). Conversely, frequencies of CD27−IgD− B cells and CD27+CD38+ PB were often robustly increased (Fig. 4, A and B). In some cases, PB represented \u003e30% of circulating B cells, similar to levels observed in acute Ebola or Dengue virus infections (42, 43). However, these PB responses were only observed in ~2/3 of patients, with the remaining patients displaying PB frequencies similar to HD and RD (Fig. 4B). KI67 expression was markedly elevated in all B cell subpopulations in COVID-19 patients compared to either control group (Fig. 4C). This observation suggests a role for an antigen-driven response to infection and/or lymphopenia-driven proliferation. Higher KI67 in PB may reflect recent generation in the COVID-19 patients compared to HD or RD. CXCR5 expression was also reduced on all major B cell subsets in COVID-19 patients (Fig. 4D). Loss of CXCR5 was not specific to B cells, however, as expression was also decreased on non-naïve CD4 T cells (Fig. 4E). Changes in the B cell subsets were not associated with co-infection, immune suppression, or treatment with steroids or other clinical features, though a possible negative association of IL-6 and PB was revealed (fig. S5A). These observations suggest that the B cell response phenotype of COVID-19 disease was not simply due to systemic inflammation."}

2_test

{"project":"2_test","denotations":[{"id":"32669297-25775592-135105208","span":{"begin":517,"end":519},"obj":"25775592"},{"id":"32669297-22238318-135105209","span":{"begin":521,"end":523},"obj":"22238318"}],"text":"B cell subpopulations were also altered in COVID-19 disease. Whereas naïve B cell frequencies were similar in COVID-19 patients and RD or HD, the frequencies of class-switched (IgD−CD27+) and not-class-switched (IgD+CD27+) memory B cells were significantly reduced (Fig. 4A). Conversely, frequencies of CD27−IgD− B cells and CD27+CD38+ PB were often robustly increased (Fig. 4, A and B). In some cases, PB represented \u003e30% of circulating B cells, similar to levels observed in acute Ebola or Dengue virus infections (42, 43). However, these PB responses were only observed in ~2/3 of patients, with the remaining patients displaying PB frequencies similar to HD and RD (Fig. 4B). KI67 expression was markedly elevated in all B cell subpopulations in COVID-19 patients compared to either control group (Fig. 4C). This observation suggests a role for an antigen-driven response to infection and/or lymphopenia-driven proliferation. Higher KI67 in PB may reflect recent generation in the COVID-19 patients compared to HD or RD. CXCR5 expression was also reduced on all major B cell subsets in COVID-19 patients (Fig. 4D). Loss of CXCR5 was not specific to B cells, however, as expression was also decreased on non-naïve CD4 T cells (Fig. 4E). Changes in the B cell subsets were not associated with co-infection, immune suppression, or treatment with steroids or other clinical features, though a possible negative association of IL-6 and PB was revealed (fig. S5A). These observations suggest that the B cell response phenotype of COVID-19 disease was not simply due to systemic inflammation."}

PMC:7402624 / 26492-28081 JSONTXT

Annnotations TAB JSON ListView MergeView

PMC:7402624 / 26492-28081 JSON TXT